{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:38:25Z","timestamp":1768322305931,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.05.018","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T06:45:22Z","timestamp":1623480322000},"page":"4210-4218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England"],"prefix":"10.1016","volume":"39","author":[{"given":"David","family":"Mesher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra","family":"Linley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Edmundson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Checchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Waterboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-9949","authenticated-orcid":false,"given":"Noemi","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-6568","authenticated-orcid":false,"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.018_b0005","unstructured":"Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008\/09 to 2013\/14. A review of the full six years of the three-dose schedule. 2015 [cited 2016 May]; Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/412264\/HPV_Vaccine_Coverage_in_England_200809_to_201314.pdf."},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.018_b0010","doi-asserted-by":"crossref","first-page":"e0150107","DOI":"10.1371\/journal.pone.0150107","article-title":"HPV serology testing confirms high HPV immunisation coverage in England","volume":"11","author":"Mesher","year":"2014","journal-title":"PLoS.One."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.018_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/sextrans-2016-052626","article-title":"Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16\/18) vaccination programme in England: an ecological analysis","volume":"93","author":"Canvin","year":"2017","journal-title":"Sex Transm Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.018_b0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jit361","article-title":"Declining genital Warts in young women in england associated with HPV 16\/18 vaccination: an ecological study","volume":"208","author":"Howell-Jones","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.018_b0025","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.018_b0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ije\/19.1.205","article-title":"Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls","volume":"19","author":"RODRIGUES","year":"1990","journal-title":"Int J Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.018_b0035","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2005.052381","article-title":"Multiplex Human Papillomavirus Serology Based on In Situ-Purified Glutathione S-Transferase Fusion Proteins","volume":"51","author":"Waterboer","year":"2005","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.vaccine.2021.05.018_b0040","doi-asserted-by":"crossref","first-page":"12692","DOI":"10.1128\/JVI.01582-09","article-title":"Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses","volume":"83","author":"Senger","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.018_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/viro.1997.8591","article-title":"Chimeric papillomavirus-like particles","volume":"234","author":"M\u00fcller","year":"1997","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.018_b0050","doi-asserted-by":"crossref","first-page":"e0005230","DOI":"10.1371\/journal.pntd.0005230","article-title":"Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies","volume":"11","author":"Migchelsen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.018_b0055","doi-asserted-by":"crossref","first-page":"e1000091","DOI":"10.1371\/journal.ppat.1000091","article-title":"Seroprevalence of 34 human papillomavirus types in the German general population","volume":"4","author":"Michael","year":"2008","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.018_b0060","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.05.018_b0065","article-title":"Analysis of matched case-control studies","volume":"352","author":"Pearce","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.05.018_b0070","unstructured":"Public Health England. Human papillomavirus (HPV): the green book, chapter 18a. 2019 12\/09\/2019]; Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/828868\/Greenbook_chapter_18a.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.018_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/sextrans-2013-051179","article-title":"Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services","volume":"90","author":"Sacks","year":"2014","journal-title":"Sex Transm Infect"},{"issue":"34","key":"10.1016\/j.vaccine.2021.05.018_b0080","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1016\/j.vaccine.2014.06.011","article-title":"Association between human papillomavirus vaccine status and other cervical cancer risk factors","volume":"32","author":"Bowyer","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.018_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/pubmed\/fdt042","article-title":"Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study","volume":"36","author":"Fisher","year":"2014","journal-title":"J Public Health (Oxf)"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.018_b0090","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1017\/S095026881000066X","article-title":"Human papillomavirus vaccination and social inequality: results from a prospective cohort study","volume":"139","author":"Roberts","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2021.05.018_b0095","doi-asserted-by":"crossref","unstructured":"Hughes, A., et al., Coverage of the English National HPV Immunisation Programme (2008-2011) among 12-17 year old females by area-level deprivation score. Euro Surveill, 2013. 19(2): p. pii: 20677.","DOI":"10.2807\/1560-7917.ES2014.19.2.20677"},{"issue":"46","key":"10.1016\/j.vaccine.2021.05.018_b0100","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.vaccine.2015.09.071","article-title":"Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years","volume":"33","author":"Petr\u00e1\u0161","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.018_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jinf.2017.01.007","article-title":"No evidence for cross-protection of the HPV-16\/18 vaccine against HPV-6\/11 positivity in female STI clinic visitors","volume":"74","author":"Woestenberg","year":"2017","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.018_b0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010\u20132016","volume":"218","author":"Mesher","year":"2018","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.018_b0115","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/OLQ.0b013e31820bc880","article-title":"Prevalence of human papillomavirus antibodies in males and females in England","volume":"38","author":"Desai","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.018_b0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.018_b0125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","article-title":"The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK","volume":"87","author":"Woodhall","year":"2011","journal-title":"Sex Transm Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:59:37Z","timestamp":1759402777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X21005806"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}